A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T)
cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic
leukemia (B-ALL)